| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16622 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
1994-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1996-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H08507784-A |
| titleOfInvention |
Virus vaccine |
| abstract |
(57) [Summary] The present application provides a drug containing a non-retroviral mutant virus (particularly HSV-1 and / or HSV-2) whose genome is defective in a gene essential for producing an infectious virus. It is provided. This virus infects normal cells and then replicates in those cells and can express viral antigen genes but is unable to produce normally infectious virus. This medicine is used for causing an immune response in a patient infected with a normal infectious virus to prevent or treat. When the non-retroviral virus is herpes simplex virus, such as HSV-1 or HSV-2, vaccines and therapeutic drugs whose defective portion is in the gH gene of glycoprotein, especially intraepithelial, oral, vaginal and Provided for intranasal administration. Also provided is the use of the HSV-1 based mutants for the manufacture of a medicament for causing an immune response in a patient against HSV type 2 infection for use in prevention or treatment. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017510262-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021088590-A |
| priorityDate |
1993-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |